Tumor-specific T cell response in response to tumor antigens MAGE-A4, PRAME and Survivin. T cell specificity to MAGE-A4 , PRAME, and Survivin both at baseline and post-therapy across both treatment arms (A) as measured by ELISpot in IFNγ SFC/100,000 cells (total n =144 and 72 per treatment arm) and (B) split by treatment arms (but due to numbers, without statistical relevance).